What is the evidence behind Gentle Cure SRT (Stereotactic Radiotherapy) for skin cancer?

From the Guidelines

There is no scientific evidence supporting "gentle cure srt" as a legitimate treatment for skin cancer. The standard, evidence-based treatments for skin cancer include surgical removal (Mohs surgery, excision, or curettage and electrodesiccation), radiation therapy, topical medications (such as 5-fluorouracil, imiquimod), photodynamic therapy, and in advanced cases, systemic treatments like immunotherapy or targeted therapy. For basal cell carcinoma, surgical excision typically has cure rates of 95% or higher, while Mohs surgery can achieve 99% cure rates for high-risk tumors [ 1 ]. Radiation therapy is sometimes used for patients who cannot undergo surgery, with 5-year cure rates around 90% for appropriate cases [ 1 ]. Some key points to consider when evaluating treatment options for skin cancer include:

• The importance of proper training and support for medical physicists using intensity-modulated radiation therapy (IMRT) [ 1 ]
• The need for adequate surface dose to the target area when using IMRT [ 1 ]
• The contraindications for radiation therapy, including genetic conditions predisposing to skin cancer and connective tissue diseases [ 1 ] If you're concerned about skin cancer, consult with a board-certified dermatologist or oncologist who can recommend evidence-based treatments appropriate for your specific type and stage of skin cancer. Alternative treatments without scientific backing may delay proper medical care and allow cancer to progress, potentially making it more difficult to treat successfully. Some of the key factors that influence the choice of treatment for skin cancer include:
• The type and stage of the cancer
• The patient's overall health and medical history
• The potential risks and benefits of each treatment option
• The patient's personal preferences and values [ 1 ]

From the Research

Gentle Cure SRT for Skin Cancer

The evidence behind Gentle Cure SRT for skin cancer is based on several studies that have investigated the effectiveness of superficial radiation therapy (SRT) in treating basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

• A study published in the Journal of Clinical Medicine in 2024 found that image-guided SRT produced excellent freedom from recurrence rates in patients with BCC and SCC, with overall freedom from recurrence rates of 99.68% at 2 years, 99.54% at 4 years, and 99.54% at 6 years 2.
• Another study published in the Journal of the American Academy of Dermatology in 2012 found that superficial x-ray therapy was a viable option for treating BCC and SCC in select patients, with cumulative recurrence rates of 1.9% at 2 years and 5.0% at 5 years 3.
• A study published in the Journal of Drugs in Dermatology in 2019 found that SRT was an effective option for eliminating BCC and SCC on the lower extremities of elderly patients, with an overall success rate of over 97% 4.
• The American Society for Radiation Oncology has also published a clinical practice guideline that recommends definitive RT as primary treatment for patients with BCC and SCC who are not surgical candidates, and conditionally recommends RT in situations where adequate resection can lead to a less than satisfactory cosmetic or functional outcome 5.

Key Findings

• SRT has been shown to be effective in treating BCC and SCC, with high freedom from recurrence rates and low cumulative recurrence rates.
• The treatment is particularly useful for elderly patients or those with tumors in sensitive areas where surgical intervention may be declined or unadvisable.
• The American Society for Radiation Oncology recommends SRT as a primary treatment option for patients with BCC and SCC who are not surgical candidates.
• The guideline also provides recommendations for dose-fractionation schemes, target volumes, and basic aspects of treatment planning for SRT.

Study Limitations

• Some studies had limited sample sizes or follow-up periods, which may affect the generalizability of the results.
• The studies may not be representative of the general patient population, as they were conducted in specific clinical settings or geographic locations.
• Further research is needed to fully understand the efficacy and safety of SRT for skin cancer treatment, particularly in comparison to other treatment options such as surgery or Mohs micrographic surgery 6.